Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias that is in Phase 3 clinical trial.
The company also develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 386 |
| CEO | Brian Goff |
Contact Details
Address: 88 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 649 8600 |
| Website | agios.com |
Stock Details
| Ticker Symbol | AGIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001439222 |
| CUSIP Number | 00847X104 |
| ISIN Number | US00847X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Goff M.B.A. | Chief Executive Officer and Director |
| Cecilia Jones | Chief Financial Officer |
| James William Burns | Corporate Secretary and Chief Legal Officer |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| Tsveta Milanova | Chief Commercial Officer |
| Dr. Lewis Clayton Cantley Ph.D. | Founder |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Founder |
| Dr. Craig B. Thompson M.D. | Founder |
| Dr. Shin-San Su Ph.D. | Founder |
| T. J. Washburn | Vice President, Controller and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 4, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 144 | Filing |